Arbutus Biopharma Corp (ABUS): Total Assets
$94.62M
As of 2025-12-31
$274.02M
As of 2026-06-30
-21.5%
3-year compound annual growth
-7.1%
5-year compound annual growth
-18.3%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $94.62M | -28.2% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $131.71M | -8.8% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $144.40M | -26.1% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $195.42M | -4.4% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $204.49M | +49.2% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $137.08M | +29.9% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $105.53M | -53.7% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $227.91M | -3.9% | 2020-03-05, Balance as of period end |
| 2017-12-31 | $237.16M | -14.0% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $275.92M | -61.3% | 2018-03-16, Balance as of period end |
| 2015-12-31 | $712.29M | +502.7% | 2017-03-22, Balance as of period end |
| 2014-12-31 | $118.18M | +64.8% | 2016-03-09, Balance as of period end |
| 2013-12-31 | $71.72M | n/a | 2015-03-13, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $94.62M | -28.2% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $50.24M | +36.3% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $91.52M | -41.8% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $6.96M | -12.2% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $277.17M | +70.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $224.95M | +195.8% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $21.44M | -9.2% |
| uniQure N.V. (QURE) | 2025-12-31 | $824.91M | +48.2% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $141.31M | -19.5% |
Compare ABUS, IRD, PYXS, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗